These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 37379548)
1. Autoimmune encephalitis related to nivolumab followed by tumor regression. Mysler SJ; Perazzo F; Mandó P Medicina (B Aires); 2023; 83(3):479-483. PubMed ID: 37379548 [TBL] [Abstract][Full Text] [Related]
2. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214 [TBL] [Abstract][Full Text] [Related]
3. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370 [TBL] [Abstract][Full Text] [Related]
5. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545 [TBL] [Abstract][Full Text] [Related]
6. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer. Takada S; Murooka H; Tahatsu K; Yanase M; Umehara K; Hashishita H; Toru H; Satoru M; Sagawa T; Fujikawa K; Sato H; Mino K Asian Pac J Cancer Prev; 2022 Feb; 23(2):695-701. PubMed ID: 35225483 [TBL] [Abstract][Full Text] [Related]
7. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G Front Immunol; 2022; 13():984132. PubMed ID: 36189265 [TBL] [Abstract][Full Text] [Related]
8. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Vitale MG; Pipitone S; Venturelli M; Baldessari C; Porta C; Iannuzzi F; Basso U; Scagliarini S; Zucali PA; Galli L; Rossetti S; Caserta C; Bracarda S; Iacovelli R; Masini C; Cortellini A; Di Girolamo S; Buti S; Fornarini G; Carrozza F; Santoni M; Caputo F; Giaquinta S; Balduzzi S; D'Amico R; Vitale G; Mighali P; Sabbatini R Clin Genitourin Cancer; 2020 Dec; 18(6):477-488. PubMed ID: 32732112 [TBL] [Abstract][Full Text] [Related]
9. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. Lolli C; Medri M; Ricci M; Schepisi G; Filograna A; De Giorgi U; Stanganelli I Medicine (Baltimore); 2018 Dec; 97(52):e13810. PubMed ID: 30593172 [TBL] [Abstract][Full Text] [Related]
10. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177 [TBL] [Abstract][Full Text] [Related]
13. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report. Guidi A; Violati M; Blasi M; Ferrari E; Luciani A; Codecà C; Ferrari D Tumori; 2020 Dec; 106(6):NP23-NP28. PubMed ID: 32851941 [TBL] [Abstract][Full Text] [Related]
14. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171 [TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G; J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023 [TBL] [Abstract][Full Text] [Related]
16. Case Report of Immuno-Oncotherapy (IO) Provoked Encephalitis Mimicking Brain Metastasis in a Patient with History of Traumatic Brain Injury. Bross SP; Mongelluzzo GJ; Conger AR; Patel MA; Vadakara J; Grant M; Gatson NTN World Neurosurg; 2020 Jul; 139():483-487. PubMed ID: 32360731 [TBL] [Abstract][Full Text] [Related]
17. Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma. Irifuku T; Satoh A; Tani H; Mandai K; Masaki T CEN Case Rep; 2020 Feb; 9(1):48-54. PubMed ID: 31605271 [TBL] [Abstract][Full Text] [Related]
18. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593 [TBL] [Abstract][Full Text] [Related]
19. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. Kobayashi K; Iikura Y; Hiraide M; Yokokawa T; Aoyama T; Shikibu S; Hashimoto K; Suzuki K; Sato H; Sugiyama E; Tajima M; Hama T In Vivo; 2020; 34(5):2647-2652. PubMed ID: 32871795 [TBL] [Abstract][Full Text] [Related]
20. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]